RCT | Pharmacogenomic testing for drug-gene interactions provides little benefit for the remission of symptoms in major depressive disorder.

Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress – JAMA (free for a limited period)

Commentary: Does Pharmacogenomic Testing Improve Outcomes in Major Depressive Disorder? — The evidence is unclear – MedPage Today (free registration required)

Commentary on Twitter

In this randomized clinical trial, pharmacogenomic testing for drug-gene interactions in major depressive disorder reduced prescription of medications with predicted drug-gene interactions but had small and nonpersistent effects on symptom remission. https://t.co/Z2OIK3h1Bo pic.twitter.com/8eKSipfBFN

— JAMA (@JAMA_current) July 12, 2022